Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: A systematic review of the evidence from comparative trials

American Journal of Infection Control

Volumn 35, Issue 2, 2007, Pages 106-114

  Falagas, Matthew E ^a,b,c   Bliziotis, Ioannis A ^a   Fragoulis, Konstantinos N ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BACITRACIN; CIPROFLOXACIN; CLOXACILLIN; METICILLIN; MINOCYCLINE; PSEUDOMONIC ACID; RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LEUKOPENIA; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; RASH; REVIEW; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; VOMITING;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; CARRIER STATE; CLINICAL TRIALS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MALE; METHICILLIN RESISTANCE; RANDOMIZED CONTROLLED TRIALS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME;

EID: 33847157170     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2006.09.005     Document Type: Review

References (61)

1. Wertheim H., Melles D.C., Vos M.C., van Leeuwen W., van Belkum A., Verbrugh H.A., et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5 (2005) 751-762
2. Kluytmans J., van Belkum A., and Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 10 (1997) 505-520
3. Sewell C.M., Clarridge J., Lacke C., Weinman E.J., and Young E.J. Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA 248 (1982) 1493-1495
4. Jensen A.G., Wachmann C.H., Poulsen K.B., Espersen F., Scheibel J., Skinhoj P., et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 159 (1999) 1437-1444
5. Davis K.A., Stewart J.J., Crouch H.K., Florez C.E., and Hospenthal D.R. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 39 (2004) 776-782
6. Dombros N., Dratwa M., Feriani M., Gokal R., Heimburger O., Krediet R., et al. European best practice guidelines for peritoneal dialysis. 3 peritoneal access. Nephrol Dial Transplant 20 (2005) ix8-x12
7. Aly R., Maibach H.I., Shinefield H.R., Mandel A., and Strauss W.G. Bacterial interference among strains of Staphylococcus aureus in man. J Infect Dis 129 (1974) 720-724
8. Grosset J., and Leventis S. Adverse effects of rifampin. Rev Infect Dis 5 (1983) S440-S450
9. Lee C.H., and Lee C.J. Thrombocytopenia-a rare but potentially serious side effect of initial daily and interrupted use of rifampicin. Chest 96 (1989) 202-203
10. Kleinknecht D., Homberg J.C., and Decroix G. Acute renal failure after rifampicin. Lancet 1 (1972) 1238-1239
11. Falagas ME, Fragoulis KN, Bliziotis IA. Oral rifampin for prevention of S. aureus carriage-related infections in patients with renal failure-a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006 May 16;[Epub ahead of print].
12. Archer G.L., and Armstrong B.C. Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis. J Infect Dis 147 (1983) 642-649
13. Bernardini J., Piraino B., Holley J., Johnston J.R., and Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 27 (1996) 695-700
14. Blowey D.L., Waraday B.A., and McFarland K.S. The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. Adv Perit Dial 10 (1994) 297-299
15. Campos M.A., Arias A., Rodriguez C., Dorta A., Betancor L., Lopez-Aguado D., et al. Etiology and therapy of chronic suppurative otitis. J Chemother 7 (1995) 427-431
16. Chandler M.H., Toler S.M., Rapp R.P., et al. Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients. Antimicrob Agents Chemother 34 (1990) 442-447
17. Chatzinikolaou I., Finkel K., Hanna H., Boktour M., Foringer J., Ho T., et al. Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med 115 (2003) 352-357
18. D'Addato M., Curti T., and Freyrie A. Prophylaxis of graft infection with rifampin-bonded Gelseal graft: 2-year follow-up of a prospective clinical trial. Italian Investigators Group. Cardiovasc Surg 4 (1996) 200-204
19. Darouiche R., Wright C., Hamill R., et al. Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin. Antimicrob Agents Chemother 35 (1991) 1612-1615
20. de Fijter C.W., ter Wee P.M., and Verbrugh H.A. Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (C) APD-related peritonitis: a prospective randomized multicenter comparison (CIPPER trial). Perit Dial Int 21 (2001) 480-486
21. Dowzicky M., Nadler H.L., Feger C., et al. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. Am J Med 104 (1998) 34S-42S
22. Drancount M., Stein A., Argenson J.N., Zannier A., Curvale G., Raoult D., et al. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 37 (1993) 1214-1218
23. Drusano G.L., Townsend R.J., Walsh T.J., et al. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrob Agents Chemother 30 (1986) 42-45
24. Flanigan M.J., Hochstetler L.A., Langholdt D., and Lim V.S. Continuous ambulatory peritoneal dialysis catheter infections: diagnosis and management. Perit Dial Int 14 (1994) 248-254
25. Gosbell I.B. Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am J Clin Dermatol 5 (2004) 239-259
26. Govender S.T., Nathoo N., and van Dellen J.R. Evaluation of an antibiotic-impregnated shunt system for the treatment of hydrocephalus. J Neurosurg 99 (2003) 831-839
27. Hernandez-Richter T., Wittmann F., Mayr S., et al. Experimental examination concerning the efficacy of silver-coated Dacron prostheses in vascular graft infections following subcutaneous implantation in a standardized infection model. Zentralbl Chir 128 (2003) 244-249
28. Isiklar Z.U., Demirors H., Akpinar S., et al. Two-stage treatment of chronic staphylococcal orthopaedic implant-related infections using vancomycin, impregnated PMMA spacer and rifampin containing antibiotic protocol. Bull Hosp Joint Dis 58 (1999) 79-85
29. Levine D.P., Fromm B.S., and Reddy B.R. Slow response to vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 115 (1991) 674-680
30. Loeb M., Main C., Walker-Dilks C., and Eady A. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 4 (2003) CD003340
31. Masse A., Bruno A., Bosetti M., et al. Prevention of pin track infection in external fixation with silver coated pins: clinical and microbiological results. J Biomed Mater Res 53 (2000) 600-604
32. McAnally T.P., Lewis M.R., and Brown D.R. Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus. Antimicrob Agents Chemother 25 (1984) 422-426
33. Muder R.R., Boldin M., Brennen C., Hsieh M., Vickers R.M., Mitchum K., et al. A controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J Antimicrob Chemother 34 (1994) 188-190
34. Norden C.W., Fierer J., and Bryant R.E. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev Infect Dis 5 Suppl 3 (1983) S495-S501
35. Norden C.W., Bryant R., Palmer D., Montgomerie J.Z., and Wheat J. Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. South Med J 79 (1986) 947-951
36. Peterson L.R., Quick J.N., Jensen B., Homann S., Johnson S., Tenquist J., et al. Emergence of ciprofloxacin resistance in nosocomial methicillin resistant Staphylococcus aureus isolates. Arch Intern Med 150 (1990) 2151-2155
37. Raad I.I., Darouiche R.O., Hachem R., Abi-Said D., Safar H., Darnule T., et al. Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin. Crit Care Med 26 (1998) 219-224
38. Ruotsalainen E., Jarvinen A., Koivula I., Kauma H., Rintala E., Lumio J., et al. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 259 (2006) 179-190
39. Sampath L.A., Tambe S.M., and Modak S.M. In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters. Infect Control Hosp Epidemiol 22 (2001) 640-646
40. Smith S.M., Eng R.H.K., and Tecson-Tumang F. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother 33 (1989) 181-184
41. Sol J., Sampimon O.C., Barkema H.W., and Schukken Y.H. Factors associated with cure after therapy of clinical mastitis caused by Staphylococcus aureus. J Dairy Sci 83 (2000) 278-284
42. Strausbaugh L.J., Jacobson C., Sewell D.L., Potter S., and Ward T.T. Antimicrobial therapy for methicillin-resistant Staphylococcus aureus colonization in residents and staff of a Veterans Affairs nursing home care unit. Infect Control Hosp Epidemiol 13 (1992) 151-159
43. Vacek V., Hejzlar M., and Pavlansky R. Study of rifampicin: I: penetration into the bone in man after single dose of 750 mg. Int Z Klin Pharmakol Ther Toxikol 3 (1970) 217-219
44. Van der Auwera P., Klastersky J., Thys J.P., Meunier-Carpentier F., and Legrand J.C. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 28 (1985) 467-472
45. Van der Auwera P., and Klastersky J. Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin. Antimicrob Agents Chemother 31 (1987) 1002-1005
46. Walsh T.J., Standiford H.C., Reboli A.C., John J.F., Mulligan M.E., and Ribner B.S. Randomized double-blinded trial with either novobiocin or trimethoprim-sulfamethixazole against methicillin resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 37 (1993) 1334-1342
47. Wheat J.L., Kohler R.B., White A.L., and White A. Effect of rifampin on nasal carriers of coagulase-positive staphylococci. J Inf Dis 144 (1981) 177
48. Yu V.L., Goetz A., Wagener M., Smith P.B., Rihs J.D., Hanchett J., et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficancy of antibiotic prophylaxis. N Engl J Med 315 (1986) 91-96
49. Yzerman E.P., Boelens H.A., Vogel M., and Verbrugh H.A. Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus. J Antimicrob Chemother 42 (1998) 233-239
50. Zimmerman S.W., Ahrens E., Johnson C.A., Craig W., Leggett J., O'Brien M., et al. Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis 18 (1991) 225-231
51. Perl T.M., Cullen J.J., Wenzel R.P., Zimmerman M.B., Pfaller M.A., Sheppard D., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346 (2002) 1871-1877
52. Rao N., Jacobs S., and Joyce L. Cost-effective eradication of an outbreak of methicillin-resistant Staphylococcus aureus in a community teaching hospital. Infect Control Hosp Epidemiol 9 (1988) 255-260
53. Munckhof W.J., Kleinschmidt S.L., and Turnidge J.D. Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study. Int J of Antimicrob Agents 24 (2004) 605-608
54. Gould I.M. Control of methicillin-resistant Staphylococcus aureus in the UK. Eur J Clin Microbiol Infect Dis 24 (2005) 789-793
55. Schito G.C. The importance of the development of antibiotic resistance in Staphylococcus aureus. Clin Microbiol Infect 12 Suppl 1 (2006) 3-8
56. Santos Sanches I., Mato R., de Lancastre H., Tomasz A., and CEM/NET Collaborators and the International Collaborators. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist 6 (2000) 199-211
57. Maple P.A., Hamilton-Miller J.M., and Brumfitt W. World-wide antibiotic resistance in meticillin-resistant Staphylococcus aureus. Lancet 1 (1989) 537-540
58. Aubry-Damon H., Soussy C.J., and Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 42 (1998) 2590-2594
59. O'Grady N.P., Alexander M., Dellinger E.P., Gerberding J.L., Heard S.O., Maki D.G., et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 51 (2002) 1-29
60. Vivoni A.M., Santos K.R., de-Oliveira M.P., Giambiagi-deMarval M., Ferreira A.L., Riley L.W., et al. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect Control Hosp Epidemiol 26 (2005) 662-7a
61. Zakrzewska-Bode A., Muytjens H.L., Liem K.D., and Hoogkamp-Korstanje J.A. Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. J Hosp Infect 31 (1995) 189-193